NCT04268472 - "Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg (Jonson&Jonson, Russia)" | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 6, 2019

Primary Completion Date

September 6, 2019

Study Completion Date

September 6, 2019

Conditions

Bioequivalence

Interventions

DRUG

GP30101

Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer

DRUG

Prezista®

Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer

DRUG

GP30101

Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer

DRUG

Prezista®

Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer

Trial Locations (1)

Yarosslavl Clinical Hospital #3, Yaroslavl